Monthly Archives: November 2011

Why the Delay on Facts Boxes?

By Ben Comer | Published: November 16, 2011
Despite a near-complete absence of criticism coming from industry, academia, clinicians and patients, the drug facts box – a concise, quantitative, easy-to-read format for presenting a drug’s risk/benefit profile in print advertisements – seems at least three years away from launch.
Posted in Advertising, FDA, Legal, Marketing, Regulatory, Strategy, patient education | Tagged | 1 Comment

Patients and Payers: Aligning Incentives in Phase IV

By Guest Blogger | Published: November 16, 2011
by Patrick Chassaigne These days, pharmaceutical and biotechnology companies need to demonstrate innovation and differentiation as they launch new products to market. Some of the critical questions asked by regulatory agencies, insurance payers, government health authorities, physicians and patients are: What is the value of this medication? How does it compare to other treatments? Is it worth the cost? For [...]
Posted in Strategy | Leave a comment

Accelerated Approvals Could Raise Risks for Patients

By Guest Blogger | Published: November 10, 2011
By Erik Greb. FDA approved 35 innovative drugs in fiscal 2011, including treatments for hepatitis C, prostate cancer, Hodgkin’s lymphoma, and lupus. This number of approvals is among the highest in the past 10 years, and it reflects the agency’s efforts to hasten patients’ access to new drugs. In the past two years, the agency’s lower [...]
Posted in Guest Blog, Regulatory, Safety | Tagged , , , , | Leave a comment

What Pharma Could Do for Occupy Wall Street

By Ben Comer | Published: November 2, 2011
Demonstrators at Zuccotti Park in New York City persevered through the first snow of the season, while reports from other U.S.-based occupations – in Denver, Oakland, Nashville and other cities – are tallying the arrests, which have become increasingly frequent, and forceful. “The whole world is watching,” a chant that gained prominence during anti-war protests [...]
Posted in Corporate Responsibility, Events, Market Access, Strategy, leadership | Tagged , | 7 Comments

The Seven-Billion Society: What's In It For Pharma?

By William Looney | Published: November 2, 2011
On Monday, the world’s population hit the 7 billion mark, repeating a pattern of largely unrestrained growth that has endured for the last century: the world is now adding roughly one billion people every 12 years. The UN Population Fund (UNPF) estimates that, barring some unforeseen demographic or environmental/development shifts, the figure will reach just [...]
Posted in Global, Op-Ed, healthcare | Tagged , , , , | 1 Comment